Biocon facility gets inspection closure report from USFDA
Biotechnology firm Biocon today said it has received the Establishment Inspection Report with 'voluntary action indicated' status from the USFDA on closure of inspection of its aseptic drug product facility.
"The US Food and Drug Administration (USFDA) has issued an Establishment Inspection Report in relation to the cGMP (current good manufacturing practice) inspection of its aseptic drug product facility that was audited between May 25 -June 3, 2017," Biocon said in a BSE filing.
"The USFDA has classified the outcome of this inspection as VAI (voluntary action indicated) and EIR states that the inspection is closed," it added.
Centre launches Chakshu facility allowing citizens to report suspected fraud communication: Check details
India vs England 5th Test Live Streaming: When and where to watch IND vs ENG test series match LIVE on mobile apps, TV, laptop, online
Rs 41,000 crore investment in city gas projects in Northeast, Jammu & Kashmir: Oil Minister Hardeep Singh Puri
Shark Tank India Season 3: From stressful life as CAs to entrepreneurs, how this Gurugram couple's yogamat business idea won 4-Shark deal
FM Nirmala Sitharaman asks GST officers to leverage tech to plug loopholes, better taxpayer services
The company has not elaborated on the VAI status.
The USFDA releases a copy of the EIR to the establishment that was the subject of an FDA or FDA-contracted inspection when the agency determines the inspection to be closed.
The stock of Biocon was trading at Rs 413.60, up 4.88 per cent from its previous close, on the BSE.
(This article has not been edited by Zeebiz editorial team and is auto-generated from an agency feed.)
10:18 AM IST